BIOMAT Database Logo BIOMAT Database Logo

[Clinical study of preoperative chemotherapy of primary breast cancer. 1. Efficacy of a combined use of CPA (endoxan) and FT-207 (or 5-FU dry syrup)]. 1982

K Komuro, and Y Hara, and Y Fujii, and M Yamazaki, and R Amano, and F Hashiguchi, and R Sakamoto, and R Nakamura, and A Shimada, and T Kurata, and H Ando, and K Nakamura

In twenty-nine cases of primary breast cancer preoperative treatment using CPA and FT-207 (or 5-FUDS) was performed to determine their efficacy. Daily dose of each anticancer drugs was as follows: CPA 50-200 mg, FT-207 200-600 mg, 5-FUDS 200 mg, p.o.. The total doses were CPA 1.8 g, FT-207 5.0g, 5-FUDS 3.4 g in average. In 11 cases (37.9%) reduction in tumor size was obtained. According to Ohboshi's criteria, over Grade II a effect was seen in 5 cases (17.2%), while Grade III effect was not seen in any of the cases. Effective cases were more frequently observed among those which received CPA at 25 mg/kg or more, or FT-207 (5-FUDS) at 80 mg/kg or more. Main side effects were G. I tract symptoms such as anorexia and nausea. To obtain definitive conclusion on the clinical significance of use of CPA and FT-207 (5-FUDS) as preoperative chemotherapy for breast cancer, further studies are required.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011300 Preoperative Care Care given during the period prior to undergoing surgery when psychological and physical preparations are made according to the special needs of the individual patient. This period spans the time between admission to the hospital to the time the surgery begins. (From Dictionary of Health Services Management, 2d ed) Care, Preoperative,Preoperative Procedure,Preoperative Procedures,Procedure, Preoperative,Procedures, Preoperative
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D005641 Tegafur Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms. 1-(2-Tetrahydrofuryl)-5-fluorouracil,1-(Tetrahydro-2-furanyl)-5-fluorouracil,5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione,FT-207,FT207,Florafur,Fluorofur,Ftorafur,Futraful,N1-(2'-Tetrahydrofuryl)-5-fluorouracil,Sunfural S,Uftoral,Utefos,FT 207
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

K Komuro, and Y Hara, and Y Fujii, and M Yamazaki, and R Amano, and F Hashiguchi, and R Sakamoto, and R Nakamura, and A Shimada, and T Kurata, and H Ando, and K Nakamura
[Clinical study on the permeability of FT-207 and 5-FU in primary lung cancer].
January 1985, Gan to kagaku ryoho. Cancer & chemotherapy,
K Komuro, and Y Hara, and Y Fujii, and M Yamazaki, and R Amano, and F Hashiguchi, and R Sakamoto, and R Nakamura, and A Shimada, and T Kurata, and H Ando, and K Nakamura
[Physiological effects and antitumor efficiency of ACNU in postoperative patients with stomach cancer--an evaluation of the treatment combined with FT-207 or 5-FU dry syrup].
March 1982, Gan to kagaku ryoho. Cancer & chemotherapy,
K Komuro, and Y Hara, and Y Fujii, and M Yamazaki, and R Amano, and F Hashiguchi, and R Sakamoto, and R Nakamura, and A Shimada, and T Kurata, and H Ando, and K Nakamura
[End result of preoperative adjuvant chemotherapy with oral 5-FU dry syrup in gastric cancer].
June 1988, Gan to kagaku ryoho. Cancer & chemotherapy,
K Komuro, and Y Hara, and Y Fujii, and M Yamazaki, and R Amano, and F Hashiguchi, and R Sakamoto, and R Nakamura, and A Shimada, and T Kurata, and H Ando, and K Nakamura
[Clinical study of serum and tissue concentrations of FT-207 and 5-FU in patients with cancer of the large intestine following preoperative application of FT-207 suppositories].
September 1982, Gan to kagaku ryoho. Cancer & chemotherapy,
K Komuro, and Y Hara, and Y Fujii, and M Yamazaki, and R Amano, and F Hashiguchi, and R Sakamoto, and R Nakamura, and A Shimada, and T Kurata, and H Ando, and K Nakamura
[A double-blind randomized comparative study of oral 5-fluorouracil (5-FU), cyclophosphamide (CPA), and 5-FU + CPA in advanced breast cancer].
January 2000, Gan to kagaku ryoho. Cancer & chemotherapy,
K Komuro, and Y Hara, and Y Fujii, and M Yamazaki, and R Amano, and F Hashiguchi, and R Sakamoto, and R Nakamura, and A Shimada, and T Kurata, and H Ando, and K Nakamura
[The serum and tissue concentration of FT-207, 5'-DFUR and 5-FU in patients with breast cancer by preoperative administration of UFT and 5'-DFUR].
February 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
K Komuro, and Y Hara, and Y Fujii, and M Yamazaki, and R Amano, and F Hashiguchi, and R Sakamoto, and R Nakamura, and A Shimada, and T Kurata, and H Ando, and K Nakamura
[Experience of a combination chemotherapy consisting of 5-FU, MMC, and FT-207--side effects against kidney].
September 1983, Gan to kagaku ryoho. Cancer & chemotherapy,
K Komuro, and Y Hara, and Y Fujii, and M Yamazaki, and R Amano, and F Hashiguchi, and R Sakamoto, and R Nakamura, and A Shimada, and T Kurata, and H Ando, and K Nakamura
[Study on the concentration of FT-207 and 5-FU in serum, lymph nodes and tissues after administration of FT-207 suppositories].
August 1984, Gan to kagaku ryoho. Cancer & chemotherapy,
K Komuro, and Y Hara, and Y Fujii, and M Yamazaki, and R Amano, and F Hashiguchi, and R Sakamoto, and R Nakamura, and A Shimada, and T Kurata, and H Ando, and K Nakamura
[FT-207 and 5-FU concentrations in brain tumor tissues, plasma and CSF after administration of FT-207 suppository].
April 1984, Gan to kagaku ryoho. Cancer & chemotherapy,
K Komuro, and Y Hara, and Y Fujii, and M Yamazaki, and R Amano, and F Hashiguchi, and R Sakamoto, and R Nakamura, and A Shimada, and T Kurata, and H Ando, and K Nakamura
[Serum concentration of 5-FU and tegafur (FT-207) after administration of tegafur (FT-207) suppository with the colostomy].
October 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!